The future of pharmacogenetics in the treatment of heart failure

Mohamed Subhan Anwar, Muhammad Zaid Iskandar, Helen M. Parry, Alex S. Doney, Colin N. Palmer, Chim C. Lang (Lead / Corresponding author)

    Research output: Contribution to journalArticlepeer-review

    4 Citations (Scopus)
    217 Downloads (Pure)

    Abstract

    Heart failure is a common disease with high levels of morbidity and mortality. Current treatment comprises β-blockers, ACE inhibitors, aldosterone antagonists and diuretics. Variation in clinical response seen in patients begs the question of whether there is a pharmacogenetic component yet to be identified. To date, the genes most studied involve the β-1, β-2, α-2 adrenergic receptors and the renin-angiotensin-aldosterone pathway, mainly focusing on SNPs. However results have been inconsistent. Genome-wide association studies and next-generation sequencing are seen as alternative approaches to discovering genetic variations influencing drug response. Hopefully future research will lay the foundations for genotype-led drug management in these patients with the ultimate aim of improving their clinical outcome.

    Original languageEnglish
    Pages (from-to)1817-1827
    Number of pages11
    JournalPharmacogenomics
    Volume16
    Issue number16
    DOIs
    Publication statusPublished - Nov 2015

    Keywords

    • candidate genes
    • genome-wide association study
    • heart failure
    • pharmacogenetics
    • pharmacogenomics

    Fingerprint Dive into the research topics of 'The future of pharmacogenetics in the treatment of heart failure'. Together they form a unique fingerprint.

    Cite this